BR112013020913A2 - tratamento de doença de crohn fistulizante - Google Patents

tratamento de doença de crohn fistulizante

Info

Publication number
BR112013020913A2
BR112013020913A2 BR112013020913A BR112013020913A BR112013020913A2 BR 112013020913 A2 BR112013020913 A2 BR 112013020913A2 BR 112013020913 A BR112013020913 A BR 112013020913A BR 112013020913 A BR112013020913 A BR 112013020913A BR 112013020913 A2 BR112013020913 A2 BR 112013020913A2
Authority
BR
Brazil
Prior art keywords
disease treatment
crohn
fistulizing crohn
disease
fistulizing
Prior art date
Application number
BR112013020913A
Other languages
English (en)
Inventor
Anne Ruehl
Gerhard Rogler
Michael Scharl
Original Assignee
Novartis Ag
Univ Zuerich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Univ Zuerich filed Critical Novartis Ag
Publication of BR112013020913A2 publication Critical patent/BR112013020913A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

resumo patente de invenção: "tratamento de doença de crohn fistulizante". esta invenção refere-se ao campo da doença de crohn. em particular, se refere ao tratamento de fístulas na doença de crohn empregando os anticorpos anti-il-13. o anticorpo pode ser uma igg e em particular pode ser o anticorpo anti-il-13 01951/ g12.
BR112013020913A 2011-02-17 2012-02-15 tratamento de doença de crohn fistulizante BR112013020913A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161443829P 2011-02-17 2011-02-17
PCT/IB2012/050699 WO2012110968A2 (en) 2011-02-17 2012-02-15 Treatment of fistulizing crohn's disease

Publications (1)

Publication Number Publication Date
BR112013020913A2 true BR112013020913A2 (pt) 2016-10-11

Family

ID=45814532

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013020913A BR112013020913A2 (pt) 2011-02-17 2012-02-15 tratamento de doença de crohn fistulizante

Country Status (10)

Country Link
US (1) US20140050735A1 (pt)
EP (1) EP2675477A2 (pt)
JP (1) JP2014507436A (pt)
KR (1) KR20140012093A (pt)
CN (1) CN103458927A (pt)
AU (1) AU2012219117A1 (pt)
BR (1) BR112013020913A2 (pt)
CA (1) CA2826543A1 (pt)
MX (1) MX2013009529A (pt)
WO (1) WO2012110968A2 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5006330B2 (ja) * 2005-10-21 2012-08-22 ノバルティス アーゲー Ｉｌ１３に対するヒト抗体および治療的使用
PE20161133A1 (es) * 2014-02-03 2016-11-08 Novartis Ag Filtros para equipos de infusion
WO2018183932A1 (en) * 2017-03-30 2018-10-04 Progenity Inc. Treatment of a disease of the gastrointestinal tract with a il-13 inhibitor
WO2018182641A1 (en) * 2017-03-30 2018-10-04 Progenity Inc. Methods and ingestible devices for the regio-specific release of il-13 inhibitors at the site of gastrointestinal tract disease

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080044420A1 (en) * 2005-05-11 2008-02-21 Heavner George A Anti-IL-13 antibodies, compositions, methods and uses
JP5006330B2 (ja) * 2005-10-21 2012-08-22 ノバルティス アーゲー Ｉｌ１３に対するヒト抗体および治療的使用

Also Published As

Publication number Publication date
EP2675477A2 (en) 2013-12-25
AU2012219117A1 (en) 2013-08-22
MX2013009529A (es) 2016-09-21
JP2014507436A (ja) 2014-03-27
CN103458927A (zh) 2013-12-18
CA2826543A1 (en) 2012-08-23
KR20140012093A (ko) 2014-01-29
WO2012110968A2 (en) 2012-08-23
US20140050735A1 (en) 2014-02-20
WO2012110968A3 (en) 2012-11-08

Similar Documents

Publication Publication Date Title
PH12019500441A1 (en) Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
CO6680687A2 (es) Inmunoglobinas con dominio variable dual capaces de unirse a il 1 beta e il-17, composiciones farmaceúticas y conjugados de proteína de unión de las mismas
CO6690781A2 (es) Inmunoglobulinas con dominio variable dual y usos de las mismas
EA201401077A1 (ru) Биспецифические антитела к человеческому tweak и человеческому il17 и их применения
GT201200125A (es) Inmunoglobulinas con dominio variable dual y usos de las mismas
EA201391719A1 (ru) Хиназолиновые производные для лечения вирусных инфекций и дальнейших заболеваний
EA201391507A1 (ru) АНТИТЕЛА ПРОТИВ c-Kit И ИХ ПРИМЕНЕНИЕ
EA201791693A1 (ru) Гетеродимерные иммуноглобулины
ECSP13012648A (es) Inmunoglobulinas con dominio variable dual y usos de las mismas
EA201201016A1 (ru) Антидоты антикоагулянтов
EA201500132A1 (ru) Биспецифические антитела к vegf/ang-2 и их применение для лечения сосудистых глазных заболеваний
GT201200109A (es) Inmunoglobulinas con dominio variable dual y usos de las mismas
UA109658C2 (xx) Антитіло проти cgrp
CR20130074A (es) Inmunoglobulinas con dominio variable dual y usos de las mismas
UY33707A (es) Inmunoglobulinas con dominio variable dual y usos de las mismas
BR112014008819A2 (pt) métodos para o tratamento de síndrome de vazamento vascular e câncer
CL2014001640A1 (es) Composiciones y metodos para anticuerpos dirigidos factor de p; y usos del anticuerpo.
EA201490778A1 (ru) АНТИТЕЛА ПРОТИВ HtrA1 И СПОСОБЫ ПРИМЕНЕНИЯ
PE20161032A1 (es) Anticuerpos anti-tau(ps422) humanizados y metodos de utilizacion
GT201200252A (es) Anticuerpos monoclonales optimizados contra el inhibidor de la vía del factor tisular (tfpi)
EA201491357A1 (ru) Анти-lrp5 антитела и способы их применения
EA201400447A1 (ru) АНТИТЕЛА К CD1d
TN2013000388A1 (en) Anticoagulant antidotes
BR112013020913A2 (pt) tratamento de doença de crohn fistulizante
ECSP13012523A (es) Inmunoglobulinas con dominio variable dual y usos de las mismas

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]